Join our HEVnet laboratory network now! Would you like to collaborate in an international laboratory network of hepatitis E virus (HEV) experts performing supranational studies and are you able to share HEV sequences in a shared reposito
Research: HPV vaccine is safe RIVM research shows no causal link between the vaccine against cervical cancer (HPV) and long-term fatigue symptoms in girls.
Disease burden and cost-of-illness of food-related pathogens in the Netherlands Each year, RIVM presents an update on the number of illnesses caused by 14 enteric pathogens (such as Salmonella, Campylobacter or Listeria) that can be transmitted by food into the human body.
One Health European Joint Programme (EJP) Expert Meeting On the 4th and 5th of June 2018, an expert meeting was held at RIVM to redefine and prioritise the topics for One Health research and integrative activities in Europe.
People who eat meat do not carry more ESBL bacteria RIVM research reveals that people who eat meat regularly do not carry ESBLs more frequently than vegetarians.
PhD dissertation: Dutch Q fever epidemic in 'One Health' context Today Barbara Schimmer will be defending her PhD dissertation entitled The Q fever epidemic in the Netherlands in a One Health context, at Utrecht University.
Lyme disease cases have quadrupled According to a survey by RIVM , 27,000 people were infected with Lyme disease in 2017. In 2014, the last time RIVM reported on the incidence of tick-borne disease, this number was 25,000.
Chance of ESBL contamination via livestock farming is small ESBL is an enzyme, produced by certain bacteria, which makes these bacteria resistant to antibiotics.
Dutch collaboration in One Health European Joint Programme (EJP) RIVM, Wageningen Bioveterinary Research (WBVR) and the Netherlands Centre for One Health (NCOH) are involved in a recently granted One Health European Joint Programme which will start in January 20
Lyme disease costs EUR 20 million annually The societal costs of Lyme disease have been determined for the Netherlands for the first time. The disease appears to cost nearly EUR 20 million each year.